Clinical pretreatment risk factors and Ga-67 scintigraphy early during treatment for prediction of outcome of patients with aggressive non-Hodgkin lymphoma

Cancer

Volumn 94, Issue 4, 2002, Pages 873-878

  Israel, Ora ^a,b   Mor, Maya ^a,b   Epelbaum, Ron ^a,b   Frenkel, Alex ^a,b   Haim, Nissim ^a,b   Dann, Eldad J ^a,b   Gaitini, Diana ^a,b   Bar Shalom, Rachel ^a,b   Kolodny, Gerald M ^a,b   Front, Dov ^a,b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Aggressive non Hodgkin lymphoma (NHL); Ga 67 scintigraphy; Pre treatment risk factors; Prediction of outcome

Indexed keywords

CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GALLIUM 67; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHILD; DISEASE SEVERITY; FEMALE; HUMAN; LYMPHOMA CELL; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SCINTIGRAPHY; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GALLIUM RADIOISOTOPES; HEALTH STATUS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 0037083382     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10344     Document Type: Article

References (21)

1. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced NonHodgkin's lymphoma
2. CHOP may have been part of the beginning but certainly not the end: Issues in risk-related therapy of large-cell lymphoma
3. A predictive model for aggressive non-Hodgkin's lymphoma
4. Uptake of Gallium-67 citrate and [2-H3] deoxyglucose in the tumor model, following chemotherapy and radiotherapy
5. Gallium-67 imaging in monitoring lymphoma response to treatment
6. Ga-67 SPECT before and after treatment of lymphoma
7. Gallium-67 imaging: A predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphomas
8. The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients
9. Prediction of outcome of patients with Hodgkin's disease by Ga-67 scintigraphy after one cycle of chemotherapy
10. Early prediction of outcome in aggressive NonHodgkin's lymphoma patients by Ga-67 scintigraphy
11. Early restaging Gallium scans predict outcome in poor-prognosis patients with aggressive NonHodgkin's lymphoma treated with highdose CHOP chemotherapy
12. Negative interim gallium scanning predicts successful outcome in patients with diffuse large cell lymphoma
13. A critical assessment of the prognostic value of gallium-67 scintigraphy in lymphoma
14. Oncological Applications of FDG PET imaging: Brain tumors, colorectal cancer, lymphoma and melanoma
15. PET imaging in oncology
16. Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose
17. Whole-body positron emission tomography using F-18 fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
18. Comparison of FDG-PET and Ga-67 SPECT in the staging of lymphoma
19. F-18 Fluorodeoxuglucose imaging with coincidence dual-head gamma camera (hybrid FDG-PET) for staging of lymphoma: Comparison with ga-67 scintigraphy
20. F-18 FDG imaging of lymphoma in children using a hybrid PET system: Comparison with Ga-67
21. Ga-67 scintigraphy and F-18 FDG coincidence imaging in the evaluation of lymphoma